TWI353257B - - Google Patents
Download PDFInfo
- Publication number
- TWI353257B TWI353257B TW92122190A TW92122190A TWI353257B TW I353257 B TWI353257 B TW I353257B TW 92122190 A TW92122190 A TW 92122190A TW 92122190 A TW92122190 A TW 92122190A TW I353257 B TWI353257 B TW I353257B
- Authority
- TW
- Taiwan
- Prior art keywords
- gemcitabine
- injection
- product
- month
- solution
- Prior art date
Links
- 229960005277 gemcitabine Drugs 0.000 claims description 21
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229960005144 gemcitabine hydrochloride Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- LQICKZWUNRSEHI-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-5-[difluoro(hydroxy)methyl]-3,4-dihydroxyoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](C(O)(F)F)O1 LQICKZWUNRSEHI-BNHYGAARSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW092122190A TW200505502A (en) | 2003-08-13 | 2003-08-13 | Injection medicine of Gemcitabine solution and its manufacturing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW092122190A TW200505502A (en) | 2003-08-13 | 2003-08-13 | Injection medicine of Gemcitabine solution and its manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200505502A TW200505502A (en) | 2005-02-16 |
| TWI353257B true TWI353257B (enExample) | 2011-12-01 |
Family
ID=46727918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092122190A TW200505502A (en) | 2003-08-13 | 2003-08-13 | Injection medicine of Gemcitabine solution and its manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200505502A (enExample) |
-
2003
- 2003-08-13 TW TW092122190A patent/TW200505502A/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200505502A (en) | 2005-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525543T3 (es) | Tratamiento con pirfenidona en pacientes con función hepática atípica | |
| CN104470527B (zh) | 用于施用大环内酯抗生素的肠胃外制剂 | |
| CN102844031A (zh) | 用于治疗肝癌的有机化合物 | |
| JP2004502456A5 (enExample) | ||
| US20120093932A1 (en) | Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof | |
| JP2005538068A (ja) | 高濃度のヒト成長ホルモン（ｈＧＨ）とフェノールを含有する液剤 | |
| CZ303095B6 (cs) | Vodný intravenosní infusní roztok nebo farmaceutický roztok obsahující levosimendan | |
| CN108012527A (zh) | 苯并咪唑衍生物用于夜间酸突破的用途 | |
| JP2023507626A (ja) | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン | |
| US20220023302A1 (en) | Pde9 inhibitors for treating sickle cell disease | |
| CN101007003A (zh) | 一种稳定的托拉塞米注射液及其制备方法 | |
| KR20100017183A (ko) | 체온 저하 억제제 | |
| JP2006514665A5 (enExample) | ||
| JP3552240B2 (ja) | 高濃度ｔｃｆ製剤 | |
| CN106031710A (zh) | 一种富马酸氟呐普拉赞的注射剂及其制备方法 | |
| CN102335114B (zh) | 一种稳定的布洛芬精氨酸注射剂及其制备方法 | |
| TWI353257B (enExample) | ||
| JP6498610B2 (ja) | カバジタキセル組成物 | |
| CN102349893A (zh) | 依达拉奉药物组合物 | |
| JP5718811B2 (ja) | 経口液剤 | |
| CN102342931A (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
| CN101732345A (zh) | 顺铂脊柱肿瘤缓释植入剂及其制备方法 | |
| JPH03135918A (ja) | 免疫賦活剤 | |
| CN102119920A (zh) | 一种依达拉奉注射液及制备方法 | |
| WO2023109904A1 (zh) | 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |